The Polynucleotide Is Coated With Or Encapsulated Within A Lipid Containing Material (e.g., Liposome, Etc.) Patents (Class 435/458)
-
Patent number: 7405205Abstract: Compounds and methods for modulating cell proliferation, preferably inhibiting the proliferation of tumor cells are described. Compounds that may be used to modulate cell proliferation include antisense oligonucleotides complementary to regions of the mammalian ribonucleotide reductase genes.Type: GrantFiled: May 29, 2003Date of Patent: July 29, 2008Assignee: Lorus Therapeutics Inc.Inventors: Jim A. Wright, Aiping H. Young
-
Publication number: 20080153166Abstract: Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.Type: ApplicationFiled: November 20, 2007Publication date: June 26, 2008Inventors: Leaf Huang, Xiang Gao, Frank L. Sorgi
-
Publication number: 20080152700Abstract: The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.Type: ApplicationFiled: June 1, 2004Publication date: June 26, 2008Inventors: Reza Sheikhnejad, Mina Patel Sooch, Neal Goodwin, David Olson
-
Publication number: 20080145413Abstract: This disclosure describes structural elements that enhance fusogenicity of lipids and lipid assemblies (e.g. liposomes) with biological membranes, in particular cell membranes, and use of such structures. The elements are pH sensitive in terms of charge and hydrophilicity and undergo a polar—apolar transition when exposed to low pH.Type: ApplicationFiled: December 19, 2006Publication date: June 19, 2008Inventors: Steffen Panzner, Christian Reinsch, Evgenios Siepi
-
Publication number: 20080119433Abstract: Disclosed are methods and compositions to genetically modify substantially intact cells having cosmetic function to enhance the cosmetic appearance in mammals so as to enhance and/or maintain a biochemical and/or physiological process that has a positive effect on cosmetic appearance. The methods and compositions may provide cosmetic benefits such as reduced skin sagging, increased skin thickness, reduced wrinkles, increased skin thickness and collagen content, increased skin tone and elasticity, increased skin hydration, and improved skin texture and color.Type: ApplicationFiled: July 6, 2007Publication date: May 22, 2008Inventor: Aaron Thomas Tabor
-
Publication number: 20080113017Abstract: A sterol derivative with a pKa value of between 3.5 and 8, according to the general formula cation-spacer 2-Y-spacer 1-X-sterol, wherein Y and X represent linking groups, is suggested, as well as liposomes comprising such sterol derivatives.Type: ApplicationFiled: November 2, 2007Publication date: May 15, 2008Applicant: NOVOSOM AGInventors: STEFFEN PANZNER, Gerold Endert, Stefan Fankhanel, Anja Behrens
-
Patent number: 7361640Abstract: Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.Type: GrantFiled: April 29, 2003Date of Patent: April 22, 2008Assignee: University of PittsburghInventors: Leaf Huang, Xiang Gao, Frank L. Sorgi
-
Publication number: 20080075701Abstract: A composition for magnetofecting genetic materials into cells with the assistant of an external magnetic force is described. The composition includes hydrophilic vectors, magnetic nanoparticles, and genetic materials, wherein the magnetic nanoparticles and the genetic materials are enveloped inside the hydrophilic vectors.Type: ApplicationFiled: September 21, 2006Publication date: March 27, 2008Inventors: Chin-Yih Rex Hong, Herng-Er Horng, Jui-Sheng Sun, Hong-Chang Yang, Shieh-Yueh Yang
-
Patent number: 7345025Abstract: Described are compositions and methods relating to gene therapy, particularly as applied to hematopoietic progenitor (HP) cells, to transduced cells and methods of obtaining them, and to methods of using them to provide prolonged engraftment of modified hematopoietic cells in human subjects. The invention particularly relates to ex vivo gene therapy of HP cells for treatment or prevention of HIV infection.Type: GrantFiled: July 10, 2002Date of Patent: March 18, 2008Assignee: Johnson & Johnson Research Pty. LimitedInventors: Geoffrey P. Symonds, Rafael G. Amado, Lun-Quan Sun, Janet L. MacPherson, Gregory C. Fanning, Wayne Gerlach
-
Patent number: 7341738Abstract: Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.Type: GrantFiled: September 9, 2003Date of Patent: March 11, 2008Assignee: The University of British ColumbiaInventors: Sean C. Semple, Sandra K. Klimuk, Troy Harasym, Michael J. Hope, Steven M. Ansell, Pieter Cullis, Peter Scherrer, Dan Debeyer
-
Patent number: 7335509Abstract: Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.Type: GrantFiled: December 15, 2004Date of Patent: February 26, 2008Assignee: University of PittsburghInventors: Leaf Huang, Xiang Gao, Frank L. Sorgi
-
Publication number: 20070281900Abstract: A composition of an interfering RNA comprising a double-stranded RNA (dsRNA) molecule having a double-stranded region of from about 15 to about 40 base pairs, a peptide having a hydrophobic region and a cationic region, and a non-cationic phospholipid, and uses thereof.Type: ApplicationFiled: May 2, 2007Publication date: December 6, 2007Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Kunyuan Cui, Dong Liang, David S. Sweedler
-
Patent number: 7294511Abstract: Methods for delivering nucleic acid molecules into cells and methods for measuring nucleic acid delivery into cells and the expression of the nucleic acids are provided. The methods are designed for introduction of large nucleic acid molecules, including artificial chromosomes, into cells, and are practiced in vitro and in vivo.Type: GrantFiled: March 22, 2001Date of Patent: November 13, 2007Assignee: Chromos Molecular Systems, Inc.Inventors: Gary deJong, Sandra Louise Vanderbyl, Volker Oberle, Dirk Hoekstra
-
Patent number: 7285542Abstract: Methods and compositions are provided for transgene expression in target cells. Expression constructs using an inducible amplification system to drive expression of a therapeutic gene or other gene of interest in mammalian host cells are provided, as well as methods therefor. Inducible expression of the transgenes at high levels under physiologic conditions results from induction by hyperthermic conditions relative to the basal temperature of the host cells.Type: GrantFiled: December 12, 2003Date of Patent: October 23, 2007Assignee: The Arizona Board of Regents on behalf of The University of ArizonaInventors: Tom Tsang, Eugene W. Gerner, David T. Harris, Evan Hersh
-
Patent number: 7279322Abstract: An electrospraying apparatus and/or method is used to coat particles. For example, a flow including at least one liquid suspension may be provided through at least one opening at a spray dispenser end. The flow includes at least particles and a coating material. A spray of microdroplets suspending at least the particles is established forward of the spray dispenser end by creating a nonuniform electrical field between the spray dispenser end and an electrode electrically isolated therefrom. The particles are coated with at least a portion of the coating material as the microdroplet evaporates. For example, the suspension may include biological material particles.Type: GrantFiled: March 25, 2004Date of Patent: October 9, 2007Assignee: Regents of the University of MinnesotaInventors: David Y. H. Pui, Da-Ren Chen
-
Publication number: 20070224257Abstract: Brucellosis is a disease caused by facultative intracellular bacteria of the monospecific genus Brucella melitensis. The invention in one aspect is an immunogenic nucleic acid composition comprising DNA encoding Brucella melitensis Invasion Protein B, a polypeptide with at least 95% identity thereto, or an immunologically active fragment of either of these, and an adjuvant. In another aspect, the invention is a DNA vaccine composition comprising a plasmid vector having DNA encoding a polypeptide as recited above, in which said plasmid vector is adsorbed to a liposome. Other aspects of the invention include methods of inducing an enhanced immune response to Brucella infection in an animal, methods for the differential diagnosis in an animal of brucellosis and vaccination by an immunogenic nucleic acid composition having DNA encoding any of the above-recited polypeptides, and a kit for conducting said differential diagnosis methods.Type: ApplicationFiled: March 20, 2007Publication date: September 27, 2007Applicant: The Secretary of State for Environment, Foods & Rural AffairsInventors: Nicola Commander, Stephen Spencer
-
Patent number: 7264969Abstract: An artery wall binding peptide (AWBP) based on the artery wall cell-binding domain of apolipoprotein B-100 was conjugated to a cationic backbone configured for forming a complex with a nucleic acid to produce a composition that enhances gene transfer to artery wall cells. An illustrative cationic backbone is poly(ethylene glycol)-grafted-poly(L-lysine) (PEG-g-PLL). Methods of making and using the composition for gene transfer are also described.Type: GrantFiled: November 9, 2001Date of Patent: September 4, 2007Assignee: University of Utah Research FoundationInventors: Lei Yu, Sung Wan Kim, Jae-Woon Nah
-
Patent number: 7262173Abstract: The invention relates to the use of oligonucleotide containing cationic liposomal formulations to enhance the efficacy of chemotherapy and/or radiotherapy, particularly as a means to sensitize cancerous tumor tissues to the efficiencies of chemotherapy. This is particularly advantageous in the context of treating raf expressing tumors such as breast, lung, pancreatic and prostate tumors.Type: GrantFiled: February 15, 2002Date of Patent: August 28, 2007Assignees: Georgetown University, NeoPharm, Inc.Inventors: Usha Kasid, Prafulla Gokhale, Jin Pei, Rajshree Mewani, Imran Ahmad, Anatoly Dritschilo, Aquilur Rahman
-
Patent number: 7256043Abstract: The invention provides a peptide having at least 3 amino acids comprising an amino acid sequence selected from a) X1SM [SEQ.ID.NO.:1] b) LX2HK [SEQ.ID.NO.:2] c) PSGX3ARA [SEQ.ID.NO.:9] d) SX4RSMNF [SEQ.ID. NO.:16] e) LX5HKSMP [SEQ.ID.NO.:18] in which X is a basic amino acid residue, X1 is Q or P, X2 is A or T, X3 is an acidic amino acid residue and X4 is P or Q, the invention further provides non-viral cell-targeting vector complexes and methods associated therewith.Type: GrantFiled: March 14, 2002Date of Patent: August 14, 2007Assignee: ICH Productions LimitedInventors: Stephen Lewis Hart, Michele Writer
-
Patent number: 7250403Abstract: The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or noncarrier.Type: GrantFiled: August 10, 2001Date of Patent: July 31, 2007Assignee: Dynavax Technologies CorporationInventors: Gary Van Nest, Stephen Tuck, Karen L. Fearon, Dino Dina
-
Patent number: 7238673Abstract: A method for the direct in vivo transformation of cells in and surrounding a solid tumor is disclosed. This method is based on the site-specific delivery of proteins to solid tumors and to tissue surrounding the solid tumor by direct injection of a nucleic acid sequence. In particular, this method is directed to site-specific delivery of nucleic acids encoding major histocompatibility proteins, cytokines, and toxins to a solid tumor. This technique provides for the transfer of vectors and expression of recombinant genes in vivo and allows the introduction of proteins of therapeutic or diagnostic value for the treatment of disease.Type: GrantFiled: September 25, 2001Date of Patent: July 3, 2007Assignee: The Regents of the University of MichiganInventors: Elizabeth G. Nabel, Gary J. Nabel
-
Patent number: 7223856Abstract: The present invention provides for an antisense oligonucleotide having the sequence 5?GCTCGGCGCCGCCATTTCCAG3?. The invention also provides for an antisense oligonucleotide having the sequence 5?GTCAGCGGCCATCAGCTT3?. The present invention further provides for a method for treating a neurodegenerative disorder in a subject which comprises administering to the subject a compound in an amount effective to inhibit neuronal cell death and thus treat the neurodegenerative disorder in the subject, which compound comprises the oligonucleotide 5?GCTCGGCGCCGCCATTTCCAG3? and a delivery agent. The present invention provides for a method of inhibiting trophic factor withdrawal mediated death of a cell which comprises contacting the cell with an amount of the oligonucleotide 5?GCTCGGCGCCGCCATTTCCAG3? effective to inhibit death of the cell.Type: GrantFiled: June 28, 2002Date of Patent: May 29, 2007Assignee: The Trustees of Columbia University in the City of New YorkInventors: Carol M. Troy, Michael L. Shelanski
-
Patent number: 7217572Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1? and/or HIF2?. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1? and HIF2?. Methods of using these compounds for modulation of HIF1? and/or HIF2? expression and for diagnosis and treatment of disease associated with expression of HIF1? and/or HIF2? are provided.Type: GrantFiled: November 21, 2003Date of Patent: May 15, 2007Assignee: Isis Pharmaceuticals, Inc.Inventors: Donna T. Ward, Kenneth W. Dobie, Eric G. Marcusson, Susan M. Freier
-
Patent number: 7208314Abstract: A system relating to the delivery of desired compounds (e.g., drugs and nucleic acids) into cells using pH-sensitive delivery systems. The system provides compositions and methods for the delivery and release of a compound to a cell.Type: GrantFiled: February 26, 2002Date of Patent: April 24, 2007Assignee: Mirus Bio CorporationInventors: Sean D. Monahan, Jon A. Wolff, James E. Hagstrom, Vladimir G. Budker, David B. Rozema
-
Patent number: 7192605Abstract: The present invention relates to compositions and methods for transferring nucleic acids into cells in vitro and in vivo. The compositions comprise a transfection reagent and one or more detergents. In preferred embodiments, the compositions comprise delivery systems providing nucleic acid transfer complexes that transfect cells with high efficiency.Type: GrantFiled: May 31, 2002Date of Patent: March 20, 2007Assignee: Mirus Bio CorporationInventors: Hans Herweijer, Vladimir G. Budker
-
Patent number: 7189705Abstract: The present invention provides novel and surprisingly effective methods for delivering nucleic acids to cells. These methods are based upon the discovery that the presence of endosomal membrane destabilizers (e.g., calcium) leads to a dramatic increase in the transfection efficiency of plasmids formulated as SPLP, or “stabilized plasmid-lipid particles.Type: GrantFiled: April 20, 2001Date of Patent: March 13, 2007Assignee: The University of British ColumbiaInventors: Angela M. I. Lam, Lorne R. Palmer, Pieter R. Cullis
-
Patent number: 7179593Abstract: Highly specific hammerhead ribozymes are provided that human target estrogen receptor mRNA. These ribozymes, designated RZ1 through RZ7 provide predictable mRNA cleavage products. Methods for inhibiting estrogen-dependent tumor growth, such as that characteristic of breast cancer, are also provided employing these ribozymes. One or both of the ribozymes may be used together or separately with equal efficiency. The ribozymes possess a sequence region with a catalytic core that provides the attributed catalytic activity to these ribozymes.Type: GrantFiled: June 2, 2000Date of Patent: February 20, 2007Assignee: Board of Regents, The University of Texas SystemInventors: Arun K. Roy, Yan Lavrovsky, Rakesh K. Tyagi, Chung S. Song, Bandana Chatterjee, Shuo Chen
-
Patent number: 7179796Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.Type: GrantFiled: February 7, 2003Date of Patent: February 20, 2007Assignee: Isis Pharmaceuticals, Inc.Inventors: Lex M. Cowsert, Jacqueline R. Wyatt
-
Patent number: 7173154Abstract: Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH2)l, or {(CH2)i-Y—(CH2)j}k, wherein Y is selected from the group consisting of CH2, an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by —X1-L?-X2-Z or -Z; R1–R6, independently of one another, are selected from the group consisting of H, —(CH2)p-D-Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, andType: GrantFiled: July 28, 2003Date of Patent: February 6, 2007Assignee: Invitrogen Corp.Inventors: Yongliang Chu, Malek Masoud, Gulilat Gebeyehu
-
Patent number: 7166302Abstract: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent.Type: GrantFiled: December 19, 2001Date of Patent: January 23, 2007Assignee: California Institute of TechnologyInventors: Suzie Hwang Pun, Hector Gonzalez, Mark E. Davis, Nathalie Bellocq, Jianjun Cheng
-
Patent number: 7166298Abstract: A method for immunization using genetic material is disclosed. Compositions for genetic immunization comprising cationic lipids and polynucleotides are also disclosed. Methods for using genetic immunization to produce polyclonal and monoclonal antibodies are also disclosed. A method for epitope mapping is also disclosed.Type: GrantFiled: February 10, 2005Date of Patent: January 23, 2007Assignee: Invitrogen CorporationInventors: Joel A. Jessee, William G. Hearl
-
Patent number: 7163695Abstract: The invention provides a pharmaceutical agent delivery composition comprising: (i) a transport polymer comprising a linear or branched peptide having from about 10 to about 300 amino acid residues, having from about 5 to 100% histidine residues, and optionally having from 0 to about 95% non-histidine amino acid residues; (ii) at least one pharmaceutical agent; and optionally (iii) one or more intracellular delivery components in association with the transport polymer. The invention also provides methods for using such composition to deliver the pharmaceutical agent to the interior of cells.Type: GrantFiled: December 20, 2000Date of Patent: January 16, 2007Inventor: A. James Mixson
-
Patent number: 7160727Abstract: The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy.Type: GrantFiled: November 19, 2004Date of Patent: January 9, 2007Assignee: University of Iowa Research FoundationInventors: Paul B. McCray, Jr., Beverly L. Davidson, Colleen Stein
-
Patent number: 7157098Abstract: The present invention provides a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity. This composition has a high gene transfection efficiency at non-toxic doses and is designed to transfect human bronchial premalignant lesions and early endo-bronchial malignancies.Type: GrantFiled: January 6, 1999Date of Patent: January 2, 2007Inventors: Roman Perez-Soler, Yiyu Zou
-
Patent number: 7145039Abstract: Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH2)l, or {(CH2)i-Y—(CH2)j}k, wherein Y is selected from the group consisting of CH2, an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by —X1—L?—X2—Z or —Z; R1–R6, independently of one another, are selected from the group consisting of H, —(CH2)p-D—Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, andType: GrantFiled: January 21, 2005Date of Patent: December 5, 2006Assignee: Invitrogen Corp.Inventors: Yongliang Chu, Malek Masoud, Gulilat Gebeyehu
-
Patent number: 7141375Abstract: A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.Type: GrantFiled: March 2, 2004Date of Patent: November 28, 2006Assignee: Gilead Sciences, Inc.Inventors: Kristian Pietras, Arne Ostman, Carl-Henrik Heldin, Kristofer Rubin
-
Patent number: 7132404Abstract: The present invention provides a composition of matter for introducing an exogenous nucleic acid molecule into a target cell, comprising a liposome, a ligand polymeric scaffold, wherein the ligand can bind to a cell surface receptor or molecule. The invention also provides methods for introducing an exogenous nucleic acid molecule into a target cell using the composition of matter.Type: GrantFiled: February 6, 2003Date of Patent: November 7, 2006Assignee: Regents of the Univeristy of CaliforniaInventor: Randal S. Goomer
-
Patent number: 7132529Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of stearoyl-CoA desaturase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding stearoyl-CoA desaturase. Methods of using these compounds for modulation of stearoyl-CoA desaturase expression and for treatment of diseases associated with expression of stearoyl-CoA desaturase are provided.Type: GrantFiled: July 30, 2001Date of Patent: November 7, 2006Assignee: Isis Pharmaceuticals, Inc.Inventors: Rosanne M. Crooke, Mark J. Graham
-
Patent number: 7132289Abstract: A method for introducing a foreign matter into a cell, includes the steps of placing a small particle carrying a foreign matter at a part of a cell surface of a living cell, boring a hole in a cell wall and/or a cell membrane by irradiating and treating said part of the cell surface with a laser beam, and introducing the foreign matter into the living cell.Type: GrantFiled: December 17, 2001Date of Patent: November 7, 2006Assignee: Osaka UniversityInventors: Akio Kobayashi, Kiichi Fukui, Satoshi Harajima, Eiichiro Fukusaki, Shinichiro Kajiyama, Shinya Okuda, Takeshi Shoji
-
Patent number: 7129087Abstract: Coalescence of cells or other membrane-bound entities is facilitated by anchoring an outwardly projecting first oligonucleotide in one member and an outwardly projecting second oligonucleotide, complementary to the first, in a second member and incubating under hybridizing conditions. Liposomes may be coalesced with cells to deliver hydrophilic agents thereto, such as DNA probes or drugs. Kits containing complementary oligonucleotides containing hydrophobic anchoring moieties may be used.Type: GrantFiled: October 11, 2001Date of Patent: October 31, 2006Assignee: The Public Health Research Institute of the City of New York, Inc.Inventors: Fred R. Kramer, Osama A. Alsmadi, Sanjay Tyagi
-
Patent number: 7129222Abstract: The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a nonbiodegradable microcarrier or nanocarrier.Type: GrantFiled: March 9, 2001Date of Patent: October 31, 2006Assignee: Dynavax Technologies CorporationInventors: Gary Van Nest, Stephen Tuck
-
Patent number: 7125718Abstract: A method for introducing and expressing genes in animal cells, in which the animal cells are transfected with bacterial blebs containing a eukaryotic expression cassette encoding the gene. Bacterial blebs comprising a eukaryotic expression cassette, wherein the bacterial blebs are derived from gram negative bacteria.Type: GrantFiled: May 24, 2001Date of Patent: October 24, 2006Assignee: University of Maryland Biotechnology InstituteInventors: Robert J. Powell, David Hone
-
Patent number: 7119078Abstract: The present invention relates to methods of intracellular delivery of oligonucleotides. More particularly, the present invention relates to the use of the delivery system to deliver G-quartet oligonucleotides as a cancer therapy or an anti-viral therapy.Type: GrantFiled: March 27, 2002Date of Patent: October 10, 2006Assignee: Baylor College of MedicineInventors: Naijie Jing, Weijun Xiong, Yongli Guan
-
Patent number: 7105157Abstract: The present invention relates to cells and methods for treating or preventing tumor formation or infections with pathogens in a patient. The cells of the invention are antigen-presenting cells (e.g., dendritic cells or macrophage) that have been loaded with RNA derived from tumors or pathogens. By administering the RNA-loaded antigen-presenting cells to a patient, tumor formation or pathogen infections can be treated or prevented. Alternatively, the RNA-loaded cells can be used as stimulator cells in the ex vivo expansion of CTL. Such CTL can then be used in a variation of conventional adoptive immunotherapy techniques.Type: GrantFiled: April 30, 1997Date of Patent: September 12, 2006Assignee: Duke UniversityInventors: Smita K. Nair, David J. Boczkowski, Eli Gilboa
-
Patent number: 7101995Abstract: Described is a deliverable composition with low toxicity comprising an amphipathic compound, a polycation, and a siRNA. The composition may be used in the process of delivering a siRNA to an animal cell or more particularly, a mammal cell.Type: GrantFiled: May 28, 2002Date of Patent: September 5, 2006Assignee: Mirus Bio CorporationInventors: David L. Lewis, James E. Hagstrom, Hans Herweijer, Aaron G. Loomis, Sean D. Monahan, Jon A. Wolff
-
Patent number: 7098191Abstract: Expression constructs using an inducible amplification system to drive expression of a therapeutic gene or other genes of interest in mammalian cells are provided, as well as methods of using the same.Type: GrantFiled: March 29, 2002Date of Patent: August 29, 2006Assignee: The Arizona Board of ReagentsInventors: Tom Tsang, Eugene W. Gerner, David T. Harris, Evan Hersh
-
Patent number: 7098030Abstract: An polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to a cell.Type: GrantFiled: July 26, 2004Date of Patent: August 29, 2006Assignee: Mirus Bio CorporationInventors: David B. Rozema, Vladimir G. Budker, James E. Hagstrom, Vladimir Trubetskoy, Jon A. Wolff, Sean D. Monahan, Paul M. Slattum
-
Patent number: 7098032Abstract: An polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to a cell.Type: GrantFiled: January 28, 2005Date of Patent: August 29, 2006Assignee: Mirus Bio CorporationInventors: Vladimir S. Trubetskoy, James E. Hagstrom, Vladimir G. Budker, Jon A. Wolff, David B. Rozema, Sean D. Monahan
-
Patent number: 7094605Abstract: Polyampholyte are able to condense nucleic acid to form small complexes which can be utilized in the delivery of nucleic acid to mammalian cells. The polyampholytes can be formed prior to interaction with nucleic acid or they can be formed in the presence of nucleic acid. Stabilized polycation/nucleic acid complexes can be modified to reduce the positive charge of the polycation and add targeting ligands without destabilizing the complex. The resultant particles retain their small size and are more effective in delivery of nucleic acid to cells in vivo.Type: GrantFiled: January 28, 2005Date of Patent: August 22, 2006Assignee: Mirus Bio CorporationInventors: Darren H. Wakefield, David B. Rozema, Jon A. Wolff, Vladimir Trubetskoy, James E. Hagstrom, Vladimir G. Budker, Jason Klein, So Wong
-
Patent number: 7091041Abstract: A complex is described that is deliverable to a cell comprising inserting a nucleic acid or other cargo into a reverse micelle. The reverse micelle has the property to compact the nucleic acid for easier delivery.Type: GrantFiled: July 25, 2003Date of Patent: August 15, 2006Assignee: Mirus Bio CorporationInventors: Sean D. Monahan, Jon A. Wolff, Paul M. Slattum, James E. Hagstrom, Vladimir G. Budker